Trial
NCT03781960
Abemaciclib and Nivolumab for Subjects With Hepatocellular Carcinoma
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Abramson Cancer Center at Penn Medicine
Collaborators
—
Condition
Hepatocellular Carcinoma
Intervention
Abemaciclib
Why stopped
Safety letter from sponsor
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-12-14